Other Events ·
ENDRA Life Sciences Inc. received written notice from Nasdaq on July 8, 2026, confirming it has regained compliance…
NDRAENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. received written notice from Nasdaq on July 8, 2026, confirming it has regained compliance with the Minimum Stockholders’ Equity Requirement. The company previously fell below the $2,500,000 minimum threshold reported in its 2025 Annual Report. As a result of regaining compliance, the company will be subject to a Discretionary Panel Monitor for one year starting July 1, 2026. If the company fails to maintain compliance during this monitoring period, Nasdaq may issue a delisting determination without allowing for a standard compliance plan or cure period. ENDRA Life Sciences Inc. is a life sciences company focused on medical technology.